Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for anti-Hu associated paraneoplastic neurological syndromes
NL-OMON32182Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in paraneoplastic neurological syndrome (PNS), sponsored by Erasmus MC. Primary endpoints: Functional improvement after 8 weeks and Neurological improvement after 8 weeks. Started Sep 2008; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
paraneoplastic neurological syndrome (PNS)
Beyond the preview
Go deeper on NL-OMON32182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32182.